EV/DNG (Qlaira, BAY86-5027, SH T00658K) + EV/DNG (SH T00658L)
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovulation Inhibition
Conditions
Ovulation Inhibition
Trial Timeline
Mar 1, 2003 → Feb 1, 2004
NCT ID
NCT00805415About EV/DNG (Qlaira, BAY86-5027, SH T00658K) + EV/DNG (SH T00658L)
EV/DNG (Qlaira, BAY86-5027, SH T00658K) + EV/DNG (SH T00658L) is a phase 2 stage product being developed by Bayer for Ovulation Inhibition. The current trial status is completed. This product is registered under clinical trial identifier NCT00805415. Target conditions include Ovulation Inhibition.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00805415 | Phase 2 | Completed |
Competing Products
13 competing products in Ovulation Inhibition